Clinical trials: Multicentric Castleman Disease
Idiopathic Multicentric Castleman's Disease
Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial
To explore the effectiveness and safety of Zanuburutinib in relapsed and refractory idiopathic Multicentric Castleman's disease (iMCD) patients.
- Trial name
- iMCD (NCT04743687)
- Testing
- Zanubrutinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease
Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis
Background: Some people with human immunodeficiency virus (HIV) are on antiretroviral therapy (ART). Their cells have shown to age faster than expected.
- Conditions
- Kaposi Sarcoma, KSHV Associated Multicentric Castleman Disease, Primary Effusion Lymphoma, IL-6 Related KSHV Associated Cytokine Syndrome
- Trial name
- NCT04742387
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi Sarcoma
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Background: Kaposi sarcoma (KS) is a cancer most often seen in people with HIV. It causes lesions. These are usually on the skin but sometimes in the lymph nodes, lungs, and gastrointestinal tract.
- Trial name
- NCT02659930
- Testing
- liposomal doxorubicin, pomalidomide
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoproliferative Disorder, HHV-8
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
This study will gain information about a rare disorder called KSHV-associated multicentric Castleman's disease (MCD). KSHV, a virus, causes several kinds of cancer, including some forms of MCD.
- Conditions
- Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
- Trial name
- NCT00092222
- Testing
- Etoposide, Interferon-alpha, Rituximab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Multicentric Castleman's Disease
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
The purpose of this study is to evaluate the long-term safety of siltuximab in patients with multicentric Castleman's disease (MCD).
- Trial name
- NCT01400503
- Testing
- Siltuximab
- Where
- 26 sites in United States, Belgium and 15 more
- Volunteers
- 60 people
- Sponsor
- Janssen Research & Development, LLC
Multicentric Castleman s Disease
Natural History of KSHV-Associated Multicentric Castleman s Disease
Background: Kaposi s sarcoma herpes virus (KSHV) causes several kinds of cancer, Kaposi sarcoma (KS), a form of Multicentric Castleman s Disease (MCD) and a type of lymphoma known as Primary Effusion Lymphoma (PEL).
- Trial name
- NCT04968288
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- National Cancer Institute (NCI)
Castleman's Disease (CD), Idiopathic Multicentric Castleman's Disease
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those…
- Trial name
- NCT07085039
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Pennsylvania
HIV, Kaposi's Sarcoma
Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
BACKGROUND: A number of important scientific advances can be made through the study of blood, bone marrow, tumor, or other tissue samples from patients with HIV infection, infection with Kaposi s sarcoma associated herpesvirus…
- Conditions
- HIV, Kaposi's Sarcoma, Lymphomas, Multicentric Castleman's Disease
- Trial name
- NCT00006518
- Where
- United States
- Volunteers
- 1,029 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Myeloproliferative Disorders, Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition
- Trial name
- NCT00132015
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
This phase I trial studies the side effects and best dose of ibrutinib in treating B-cell non-Hodgkin lymphoma that has returned or does not respond to treatment in patients with human immunodeficiency virus (HIV) infection.
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT02109224
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Anti IL-6R, Castleman's Disease, Multicentric
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
This study adopted a multicenter, randomized, double-blind, placebo-controlled approach with the best supportive treatment design, using recombinant humanized anti-interleukin-6 receptor monoclonal antibody injection (VDJ001) to…
- Trial name
- NCT07872423
- Testing
- Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection
- Where
- 8 sites in China
- Volunteers
- 45 people
- Sponsor
- Beijing VDJBio Co., LTD.
Castleman Disease, Castleman's Disease, Multicentric
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
- Trial name
- NCT03933904
- Testing
- Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania
Castleman's Disease
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment
This open-label, single center study will provide RoActemra/Actemra (tocilizumab) to a maximum of 4 patients with Multicentric Castelman's Disease who have demonstrated benefit from RoActemra/Actemra in study MRA004US (Chugai…
- Trial name
- NCT01183598
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche